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Background: The deubiquitinating enzyme USP33 controls several important cellular functions.
Results: HERC2 and p97 are critical for USP33 degradation.
Conclusion: HERC2 and p97 constitute a novel pathway to degrade USP33.
Significance: The HERC2/p97 degradative pathway may control USP33-dependent processes.
Because the deubiquitinating enzyme USP33 is involved in
several important cellular processes (-adrenergic receptor
recycling, centrosome amplification, RalB signaling, and cancer
cell migration), its levels must be carefully regulated. Using
quantitative mass spectrometry, we found that the intracellular
level of USP33 is highly sensitive to the activity of p97. Knock-
down or chemical inhibition of p97 causes robust accumulation
of USP33 due to inhibition of its degradation. The p97 adaptor
complex involved in this function is theUfd1-Npl4heterodimer.
Furthermore, we identified HERC2, a HECT domain-contain-
ing E3 ligase, as being responsible for polyubiquitination of
USP33. Inhibition of p97 causes accumulation of polyubiquiti-
nated USP33, suggesting that p97 is required for postubiquiti-
nation processing. Thus, our study has identified several key
molecules that controlUSP33degradationwithin the ubiquitin-
proteasome system.
USP332 is a deubiquitinating enzyme (DUB), a class of pro-
teins that regulate ubiquitin-dependent processes. By removing
monoubiquitin or disassembling polyubiquitin chains from
substrate proteins, DUBs counteract or regulate the activities of
E3 ubiquitin ligases (1, 2). USP33 has been implicated in several
important cellular functions. These functions include centro-
some amplification (3), RalB-dependent signaling (4), and recy-
cling ofmembrane receptors (5). In addition, USP33 is involved
in SLIT-dependent axon guidance and cell migration events (6,
7), as well as stabilization of type 2 iodothyronine deiodinase
which is important for supplying active thyroid hormones for
brain development (8). Many of these pathways are sensitive to
USP33 levels, as both knockdown and overexpression of USP33
result in specific cellular defects. Consequently, there appears
to be a need to tightly regulate the levels of USP33. USP33 is a
short livedDUB that is constantly turned over by the ubiquitin-
proteasome system (9).
A previous study identified USP33 as an interacting protein
of the von Hippel-Lindau protein (pVHL), an E3 ligase. pVHL-
mediated polyubiquitination was proposed to target USP33 for
degradation via the ubiquitin-proteasome system (9). However,
this study utilized in vitro assays or cellular assays with exoge-
nously expressed USP33, and the role of pVHL in regulating
endogenousUSP33 has not been validated. It therefore remains
possible that additional pathways are involved in USP33
degradation.
In this study, we have identified and characterized a num-
ber of proteins critical for regulating the intracellular levels
of USP33 using quantitative mass spectrometry, RNA inter-
ference, and biochemical approaches. These proteins consist
of p97 (also known as VCP; CDC48 in yeast), its adaptor
complex Ufd1-Npl4, and the E3 ubiquitin ligase HERC2.
Together, p97, Ufd-Npl4, and HERC2 constitute a novel
pathway to target USP33 for degradation via the ubiquitin-
proteasome system.
EXPERIMENTAL PROCEDURES
Cell Culture and Stable Isotope Labeling by Amino Acids in
Cell Culture (SILAC)—HeLa, 293T, NIH-3T3, 786-O, RCC4,
and 293 Flp-In T-Rex cells were cultured in Dulbecco’s modi-
fied Eagle’s medium (DMEM) supplemented with 10% fetal
bovine serum. 293 Flp-In T-Rex HERC2-ShB cells expressing
doxycycline-inducible and shRNA-resistantHERC2, or catalyt-
ically inactive (C4762S) HERC2 were generated by the Flp-In
T-Rex system according to the manufacturer’s instructions
(Invitrogen). 786-O and RCC4 cells stably infectedwith control
vector or HA-pVHL were kind gifts fromWilliam G. Kaelin Jr.
andwere described previously (10). For SILAC,HeLa cells were
cultured in DMEM supplemented with 10% dialyzed fetal
bovine serum (light labeling). For heavy labeling, Arg6 (U-13C6)
and Lys8 (U-13C6, U-15N2) (Cambridge Isotopes) were supple-
mented at the same concentration as in the standard DMEM
formulation.
* Thisworkwas supported, inwholeor inpart, byNational Institutes ofHealth
Grant R01 GM062967. This work was also supported by the Howard
Hughes Medical Institute.
1 Towhomcorrespondence should be addressed: California Institute of Tech-
nology, Howard HughesMedical Institute, 1200 E. California Blvd., MC114-
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2 The abbreviations used are: USP, ubiquitin-specific protease; DUB, deubiq-
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Sample Preparation for Mass Spectrometry Analysis—For
SILAC, a membrane fraction enriched with mitochondria was
prepared from a 1:1 mixture of heavy and light SILAC-labeled
HeLa p97-V1 cells (treated in the absence or presence of 1
g/ml doxycycline for 2 days). This fraction was prepared as
described previously (11). Isoelectric focusing of peptides was
performed as described previously (11).
Mass Spectrometry Analysis—Mass spectrometry experi-
ments were performed on an EASY-nLC connected to a hybrid
LTQ-Orbitrap classic (Thermo Scientific) equipped with a
nanoelectrospray ion source (ProxeonBiosystems) as described
previously (12). Peptides were separated on a 15-cm reversed-
phase analytical column (75-m internal diameter) in-house
packed with 3-m C18 beads (ReproSil-Pur C18-AQ medium;
Dr. Maisch GmbH) with a 160-min gradient from 2 to 30%
acetonitrile in 0.2% formic acid at a flow rate of 350 nl/min. The
mass spectrometer was operated in data-dependent mode to
switch automatically between full scan MS and tandem MS
acquisition. Survey full scan mass spectra were acquired in the
Orbitrap (300–1700 m/z), after accumulation of 500,000 ions,
with a resolution of 60,000 at 400m/z. The top 10 most intense
ions from the survey scan were isolated and, after the accumu-
lation of 5,000 ions, fragmented in the linear ion trap by colli-
sion-induced dissociation (collisional energy 35% and isolation
width 2 Da). Precursor ion charge state screening was enabled
and all singly charged and unassigned charge states were
rejected. The dynamic exclusion list was set with a maximum
retention time of 90 s, a relative mass window of 10 ppm. Early
expiration was enabled.
Data Analysis—Raw data files were analyzed by MaxQuant
(v 1.4.1.2) (13, 14) and searched against the UniProt human
database (15) (148,298 sequences), a contaminant database
(247 sequences), and an equally sized decoy database. The latter
consisted of reversed sequences with tryptic digestion and was
searched with a maximum of two missed cleavages, fixed car-
boxyamidomethyl modifications of cysteine, variable oxidation
modifications of methionine, and variable protein N terminus
acetylations, with 1% false discovery rate thresholds for both
peptides and proteins as estimated by the target decoy approach
(16). At least two different peptide sequences were required for
protein identification, and two different ratiomeasurements were
required for protein quantitation. Protein SILAC ratio p values
were calculated as described previously using a hierarchical boot-
strap statistical model (17).
DNA Plasmids—N-terminally 3FLAG-tagged HERC2
fragments (F1–F6) were PCR-amplified from HeLa cDNA
library and cloned into pcDNA3.1. N-terminally 3FLAG-
tagged full-length HERC2 (WT), and C4762S constructs
were cloned into pcDNA5 FRT/TO and were generated by a
combination of fusion PCR and multiple cloning steps.
N-terminal 3FLAG-tagged Npl4 and C-terminally single
FLAG-tagged Ufd1 were PCR-amplified and cloned into
pcDNA3.1(). All DNA transfection experiments were per-
formed using Lipofectamine 2000 (Invitrogen). For RNAi-
resistant USP33, silent mutations that render the construct
refractory to the USP33-ShA construct were introduced into
the coding sequence of USP33 via PCR and cloned into a
modified version of pRetroX Tet-on Advanced, where
replacement of the rtTA segment results in constitutive
expression of USP33 under the cytomegalovirus (CMV) pro-
moter. Expression of this construct was mediated via retro-
viral transduction.
Antibodies—All antibodies used in this study are commer-
cially available. The following monoclonal antibodies were
used: USP33 (clone 5B5; Sigma), actin (clone C4; Millipore),
FLAG and FLAG-peroxidase (clone M2; Sigma). The rabbit
polyclonal antibodies used were: USP33 (Millipore), USP33
(Bethyl Laboratories), USP20 (Bethyl Laboratories), p97 (Cell
Signaling), Oxa1 (Proteintech Group), HERC2 (Bethyl Labora-
tories), actin (Sigma), Npl4 (Bethyl Laboratories), UfD1 (Bethyl
Laboratories), pVHL (Thermo Scientific).
RNA Interference—Cell lines (HeLa, 293T, NIH-3T3) with
doxycycline-inducible expression of short hairpin RNA
(shRNA) against p97 were established using the TRIPZ lentivi-
ral shRNA system (Thermo Scientific). The targeted sequences
for p97-V1 andp97-V4 are 5-AACAGCCATTCTCAAACAGA-
A-3 and 5-GAATAGAGTTGTTCGGAATAA-3, respectively.
For UBXD7-V1, the targeted sequence is 5-AAGCAACGAA-
GCTGTGAAGAAT-3. In all experiments, 1 g/ml doxycycline
was used to induce shRNAexpression, and a nontargeting shRNA
was used as control (Thermo Scientific). For rescue experiments,
p97 containing silent mutations that render the construct refrac-
tory to the p97-V1 shRNA was expressed via retroviral transduc-
tion inHeLap97-V1cells.TheshRNA-resistantp97constructwas
cloned into pRetroX-Tet-On Advanced (Clontech) to replace the
rtTA-Advanced segment, resulting in constitutive expression of
p97 under the CMVpromoter. Transduced cells were selected by
1 mg/ml G418. For shRNA-mediated knockdown of USP33,
HERC2, and Npl4, the indicated cell lines were transduced with
retrovirus expressing shRNA from the human H1 promoter. The
targeted sequences were: USP33-ShA (5-GGACCAAATCTTT-
GGGCATGT-3), HERC2-ShA (5-GCCAATGTGATTGGTC-
CAATC-3), HERC2-ShB (5-GCACGCACATTGGAGATA-
TAC-3), HERC2-ShC (5-GCAGTTCCTTTCTTAGCTTCG-
3), HERC2-ShD (5-GGAAGAAAGTCATCGCCATCG-3),
Npl4-ShA (5-GCTGAAGTGGCTGCGATTTAT-3), Npl4-ShC
(5-GCGGAAGGTTGGCTGGATATT-3).
For small interfering RNA (siRNA) experiments, dicer-sub-
strate RNA (DsiRNA) duplexes were used (IDT). The target
sequences were: Npl4 siRNA1 (5-CGGTTTACATCAATAG-
AAACAAGAC-3), Ufd1 siRNA1 (5-CAAACTGACCAATA-
AGAATTCGGAC-3), nontargeting control (5-CGTTAATC-
GCGTATAATACGCGTAT-3). Transfections of siRNA were
performed using Lipofectamine RNAiMAX reagent (Invitrogen)
according to themanufacturer’s protocol.
Co-immunoprecipitation—Freshly harvested cells were
washed once in ice-cold phosphate-buffered saline (PBS) fol-
lowed by lysis in immunoprecipitation (IP) buffer (50 mM
HEPES-KOH, pH 7.0, 250mMNaCl, 5mMEDTA, 10% glycerol,
0.1% Igepal CA-630) supplemented with 1 Halt protease
inhibitors mixture (Pierce) and 10 M MG132. Cell lysis was
carried out at 4 °C with constant rotation for 1 h, and insoluble
materials were removed by centrifugation at 13,000 g for 15
min. Protein concentrations of the cleared lysates were quanti-
fied, and 1–5 mg of total protein was used for co-immunopre-
cipitation with the indicated antibodies for 2 h at 4 °C. For con-
HERC2 Targets USP33 for Degradation via p97
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trol experiments, an equal amount of purified immunoglobulin
G (IgG) from the host species was used. Protein A/G-agarose
(Pierce) was subsequently used to capture the immuno-com-
plexes (1.5 h at 4 °C), followed by four washes with IP buffer.
Bound proteins were eluted by boiling in SDS-PAGE sample
loading buffer and analyzed by SDS-PAGE and immunoblot-
ting. For immunoprecipitation of FLAG-tagged proteins, anti-
FLAGM2 affinity gel (Sigma) was used.
Affinity Purification of Polyubiquitinated Proteins—Freshly
harvested cellswerewashedonce in ice-coldPBS, followedby lysis
in IP buffer containing 0.5% Igepal CA-630, 10 mM N-ethylma-
leimide, 10 MMG132, 50 M PR-619 (LifeSensors Inc.), and 1
Halt protease inhibitorsmixture. Cleared lysateswere prepared as
described for the co-immunoprecipitationexperiments, andubiq-
uitinated proteins were affinity-purified from2mg of total pro-
tein using Ubiquilin 1 Tandem UBA (TUBE2) agarose (Boston
Biochem) at 4 °C, with constant rotation for 2 h. Bound proteins
werewashed four timesusing thesamebufferandelutedbyboiling
in SDS-PAGE sample loading buffer.
RESULTS
p97 Is Required for the Degradation of USP33—p97 is an
abundant, ubiquitously expressed member of the AAA
(ATPase associatedwith diverse cellular activities) protein fam-
ily and is involved in a broad range of cellular activities (18–20).
With help from distinct cofactor proteins and using energy
derived from ATP hydrolysis, p97 can structurally remodel or
unfold ubiquitinated client proteins (21, 22). This ability
enables p97 to function as a “segregase,” whereby it mechani-
cally extracts client proteins from their native environment.
Examples include dissociation of protein complexes or extrac-
tion of proteins from membrane surfaces. In doing so, p97 can
facilitate membrane trafficking, protein complex remodeling,
and proteasomal protein degradation (19, 20, 23).
To identify p97-regulated proteins, quantitative mass spec-
trometry was used tomeasure protein levels in amitochondria-
enriched fraction after depletion of p97. We used a HeLa cell
line (HeLa p97-V1) in which efficient silencing of p97 is
achieved via doxycycline-inducible expression of an shRNA
construct against p97 (Fig. 1A). After 2 days of p97 depletion,
the cells reproducibly showed a3.3-fold increase in the levels
of USP33 (Fig. 1B). Other DUBs in themass spectrometry data-
set were unaffected. Although we initially identified USP33
from a mitochondria-enriched fraction, other studies have
indicated localization ofUSP33 to nonmitochondrial sites, such
as the endoplasmic reticulum, Golgi, and centrosome (3, 8, 24).
We also have not found evidence for a mitochondrial localiza-
tion, and therefore our identification of USP33 in the mito-
chondrial fraction likely resulted from the high sensitivity of
mass spectrometry coupled with low level contamination of
this fraction by other cellular components. Nevertheless, these
data suggest that USP33 accumulates upon depletion of p97.
To validate the mass spectrometry results, we cultured HeLa
p97-V1 cells in the presence of doxycycline for 3 days and ana-
lyzed the steady-state levels of endogenous USP33 by immuno-
blotting total cell lysates. We found that the levels of USP33
increased up to 8-fold upon depletion of p97 (Fig. 1C). The
effect of p97 knockdown on USP33 was not limited to HeLa
cells, as similar results were obtained from the human cell line
HEK293 and the murine cell line NIH-3T3 (Fig. 1D). An inde-
pendent shRNA targeted against a different region of the p97
transcript caused similar accumulation, whereas a nontarget-
ing shRNA did not (Fig. 1E). Further arguing against an off-
target effect, expression of shRNA-resistant p97 completely
suppressed the accumulation of USP33 caused by knockdown
of endogenous p97 (Fig. 1F).
p97 facilitates the degradation of a number of proteins via the
ubiquitin-proteasome pathway (25–32). To test whether p97
regulates USP33 posttranslationally, we exogenously expressed
an RNAi-resistant version of USP33 in a modified p97-V1 cell
line where the endogenous expression of USP33 is constitu-
tively silenced. Upon knockdown of p97 via doxycycline treat-
ment, we found that the exogenously expressed USP33 also
accumulated (Fig. 1G), thus demonstrating that USP33 is reg-
ulated by p97 at a posttranslational level. Using cycloheximide
chase experiments, we compared the degradation rate of
endogenous USP33 with and without p97 activity. For these
experiments, shRNA against p97 is not ideal, because long term
knockdown of p97 results in higher starting levels of USP33.
We therefore used the recently described p97 inhibitor NMS-
873 (33, 34), which causes acute inhibition of p97 activity and
circumvents potential secondary effects that may result from
long term p97 depletion. Upon addition of cycloheximide to
inhibit new protein synthesis, USP33 degradation was moni-
tored. Addition of NMS-873 to the cycloheximide chase exper-
iment did not impact the starting levels of USP33 but caused
complete inhibition of USP33 degradation over the course of
9 h (Fig. 1H). In control cells,70% of USP33 was degraded by
9 h.We therefore conclude that the effect of p97 knockdown on
USP33 is at the level of protein degradation.
BecauseUSP33 is degraded by the ubiquitin-proteasome sys-
tem (9), we tested whether inhibition of p97 results in changes
in the polyubiquitination levels of endogenous USP33. A 12-h
treatment with NMS-873 caused a modest increase in the
steady-state levels of USP33 (Fig. 1I). Upon affinity purification
of polyubiquitinated proteins, we found a substantial increase
in the level of high molecular weight USP33 species in the
NMS-873 treated cells (Fig. 1I). These data support the notion
that p97 is important for targeting polyubiquitinatedUSP33 for
proteasomal degradation.
The p97AdaptorComplexUfd1-Npl4 Is Important forUSP33
Degradation—p97 can interact with a multitude of protein
cofactors and binding partners. These cofactor proteins are
generally thought to act as adaptors to direct p97 to its different
substrates, thereby enabling the functional diversity of p97 (22,
35–37). To elucidate which p97 cofactor regulates USP33, we
used RNAi to knockdown Npl4, a subunit of the Ufd1-Npl4
heterodimer that has been previously implicated in p97-depen-
dent proteolysis in the cytoplasm, aswell as during endoplasmic
reticulum-associated degradation and outer mitochondrial
membrane protein degradation (25, 27, 29, 30). Two shRNA
constructs against Npl4 were expressed independently via ret-
roviral transduction, and we analyzed the total cell extracts iso-
lated 48 h after infection by immunoblotting. Both shRNA con-
structs efficiently silenced endogenous Npl4 and caused
obvious accumulation of USP33 (Fig. 2A). Likewise, when the
HERC2 Targets USP33 for Degradation via p97
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expression of Ufd1 was silenced by siRNA, we also found a
similar accumulation of USP33 (Fig. 2B). These effects were
specific for the Ufd1-Npl4 complex, because knockdown of
UBXD7, another p97 cofactor, had no effect on the steady-state
levels of USP33 (Fig. 2C).
The effects of silencing Ufd1 or Npl4 on USP33 likely repre-
sent a direct involvement of the Ufd1-Npl4 heterodimer in reg-
ulating USP33, as both FLAG-Npl4 (Fig. 2D) and FLAG-Ufd1
(Fig. 2E) readily co-immunoprecipitated endogenous USP33.
Furthermore, knockdown of Npl4 (Fig. 2F) or Ufd1 (Fig. 2G)
caused accumulation of polyubiquitinated USP33. Collectively,
these data strongly suggest that the p97 adaptor Ufd1-Npl4
regulates the degradation of USP33.
The HERC2 Ubiquitin E3 Ligase Targets USP33 for p97-de-
pendent Degradation—To identify the E3 ligase important for
targetingUSP33 for degradation, we initially focused our atten-
FIGURE 1. p97 inhibition reduces the degradation of USP33. A, efficient doxycycline (dox)-induced knockdown of p97 in HeLa p97-V1 cells. HeLa cells were
transduced with retrovirus encoding doxycycline-induced shRNA against p97 and treated with the presence or absence of 1 g/ml doxycycline for the indicated
times.Total cell lysateswere isolatedandanalyzedby immunoblotting.B, SILACdatacomparingp97-depletedcellswithcontrol cells. SILAC-labeledHeLap97-V1cells
were treated in the presence (heavy-labeled) or absence (light-labeled) of 1g/ml doxycycline for 2 days to knock down p97. Amitochondria-enrichedmembrane
fraction was analyzed bymass spectrometry. The SILAC (heavy/light) ratios combined from two independent biological samples are presented. For each indicated
protein, at least 10 independent peptidemeasurementswere obtained. Error bars indicate the S.E.Asterisks indicate p value0.0001.C, analysis of USP33 levels after
p97 knockdown. HeLa p97-V1 cellswere cultured in the absence or presence of 1g/ml doxycycline (dox) for the indicated time, and total cell lysateswere analyzed
by immunoblotting againstUSP33, p97, and the loading controlOxa1.D, sameas inC, except themurine fibroblastNIH-3T3 andhumanembryonic kidney293T cells
wereused, respectively. E, sameasC, except that an independent shRNA (p97-V4) against p97wasused. For control, a nontargeting shRNAwasused. F, rescueofp97
knockdowncells.HeLap97-V1cellsexpressingemptyvectororanshRNA-resistantversionofp97 (p97R)were treatedwith1g/mldoxycycline to induceknockdown
of endogenous p97. Total cell lysateswere isolated and analyzedby immunoblotting.G, effects of p97 knockdownonexogenously expressedUSP33. p97-V1 cells in
which the endogenous expression of USP33 was constitutively silenced (USP33-ShA) were transduced with a retrovirus encoding a shRNA-resistant version of
untagged USP33 (exo USP33) where indicated. Cells were treated with or without 1 g/ml doxycycline to knock down p97 for the indicated time, and the levels of
USP33were analyzed by immunoblotting.H, analysis of USP33 degradation upon chemical inhibition of p97. HeLa cells were treatedwith 100g/ml cycloheximide
(CHX) and 10MNMS-873where indicated, and total cell lysates were analyzed by immunoblotting. I, accumulation of ubiquitinated USP33 upon inhibition of p97.
HeLacellsweretreatedwithcontrol (dimethylsulfoxide)or10MNMS-873for12h,andtotalcellularubiquitinatedproteinswereaffinity-purifiedwithTUBE2-agarose.
UbiquitinatedUSP33 (Ub-USP33) was detected by immunoblotting using anti-USP33 antibody.
HERC2 Targets USP33 for Degradation via p97
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tion on pVHL, a component of a cullin E3 ligase that had pre-
viously been implicated inmediating the proteasomal degrada-
tion of USP33 (9). However, we did not observe any significant
changes to the steady-state levels of USP33 upon ectopic
expression of pVHL in two independent renal carcinoma cell
lines, 786-O and RCC4, which are naturally deficient of pVHL
(Fig. 3A). Furthermore, knockdown of p97 in 786-O cells still
caused dramatic accumulation of USP33 (Fig. 3B). This result
indicates that pVHL is dispensable for p97-dependent degrada-
tion of USP33; however, pVHL may play a role in regulating
USP333 under other cellular conditions.
We therefore searched for other candidate E3 ligases that
may regulateUSP33.HERC2 is a giant 550-kDaHECTdomain-
containing E3 ligase that has roles in orchestrating the DNA
damage response (38), proteasomal degradation of proteins (39,
40), and regulation of centrosome morphology (41). In a pro-
teomics study, a high confidence physical interaction was iden-
tified between HERC2 and the deubiquitinating enzyme
USP20, and a potential interaction betweenHERC2 andUSP33
was suggested (42). USP20 is a homologue of USP33, and they
share60% sequence identity (43). To testwhetherHERC2 can
interact with USP33, we performed co-immunoprecipitation
FIGURE 2. The p97 adaptor Ufd1-Npl4 regulates USP33 levels. A, accumulation of USP33 upon knockdown of Npl4. HeLa cells were transduced with retrovirus
encoding control (nontargeting) shRNAor shRNAagainstNpl4. 48h after infection, total cell lysateswere isolated andanalyzedby immunoblotting.B, accumulation
ofUSP33uponknockdownofUfd1.HeLacellsweretransfectedwithcontrol (nontargeting)siRNAorsiRNAagainstUfd1.Cell lysateswere isolatedatthe indicatedtime
after transfection and analyzed by immunoblotting. C, USP33 levels uponUBXD7 knockdown. HeLa cells transducedwith doxycyline (dox)-inducible shRNA against
UBXD7were treated with 1g/ml doxycycline where indicated for 72 h, and total cell lysates were analyzed by immunoblotting.D, co-immunoprecipitation (IP) of
USP33withNpl4.HeLacellswere transiently transfectedwithpcDNAFLAG-Npl4oremptyvector (control). 40hafter transfection, total cell lysateswereprepared, and
co-immunoprecipitationwasperformedusinganti-FLAGantibodies conjugated toagarose resin.E, co-immunoprecipitationofUSP33withUfd1. Results are sameas
D, except cellswere transfectedwith FLAG-Ufd1. F, accumulationof ubiquitinatedUSP33uponknockdownofNpl4. HeLa cellswere transfectedwith control (nontar-
geting) siRNA or Npl4 siRNA1. 48 h after transfection, total ubiquitinated proteinswere affinity-purified using TUBE2-agarose. Ubiquitinated USP33was detected by
immunoblottingwith antibodies specific to USP33.G, same as in F, except Ufd1was silenced by transfection of siRNA against Ufd1.
HERC2 Targets USP33 for Degradation via p97
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FIGURE 3. pVHL is dispensable for p97-dependent degradation of USP33. A, steady-state levels of USP33 upon expression of pVHL. Total cell lysates were
isolated from 786-O or RCC4 (both naturally deficient of pVHL expression) cells stably expressing control vector or HA-tagged pVHL. Protein levels were
analyzed by immunoblotting. B, accumulation of USP33 upon p97 knockdown in 786-O cells. 786-O cells expressing control vector or HA-pVHL were trans-
duced with lentivirus encoding a doxycycline (dox)-inducible shRNA against p97 (p97-V1). Cells were treated with or without 1 g/ml doxycycline for the
indicated time, and total cell lysates were isolated and analyzed by immunoblotting.
FIGURE 4.HERC2 is an E3 ligase important for the degradation of USP33. A, co-immunoprecipitation (IP) of endogenous USP33 and USP20 with endoge-
nous HERC2. Cell lysates were prepared from HeLa cells and immunoprecipitation experiments were performed using control or anti-HERC2 antibody.
Co-immunoprecipitated proteins were detected by immunoblotting. Asterisk, nonspecific band detected by the anti-USP20 antibody. B, characterization of
HERC2-USP33 interaction. FLAG-taggedHERC2 fragmentswere transiently transfected intoHeLacells, andanti-FLAGantibodywasused to immunoprecipitate
the HERC2 fragments. Co-immunoprecipitated endogenous proteins were detected by immunoblotting. DOC, doxycyline. C, accumulation of USP33 upon
knockdown of HERC2. Control (nontargeting) shRNA or four independent shRNAs targeting different regions of the HERC2 transcript were expressed by
retroviral transduction in HeLa cells. Cell lysates were isolated and analyzed by immunoblotting. D, analysis of USP33 degradation upon HERC2 knockdown.
HeLa cells transduced with retrovirus encoding a control (nontargeting) shRNA or an shRNA against HERC2 (HERC2-ShB) were treated with 100 g/ml
cycloheximide (CHX) for the indicated time. Total cell lysates were isolated and analyzed by immunoblotting. E, rescue of HERC2 knockdown cells. 293 Flp-In
T-Rex HERC2 knockdown cells (HERC2-ShB) expressed control vector, FLAG-tagged (RNAi-resistant) wild-type (WTR), or catalytically inactive C4762S (CSR)
HERC2. To induce expression, cells were treated with 0.1 g/ml doxycycline (dox) for 40 h, and total cell lysates were analyzed by immunoblotting.
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experiments with an anti-HERC2 antibody. We found that
endogenous HERC2 could indeed interact with USP33, as well
as with USP20 (Fig. 4A). To further characterize the interaction
between these proteins, we generated a series of partially over-
lapping FLAG-tagged constructs (F1–F6) that span the entire
protein sequence of HERC2 and tested their interaction with
endogenousUSP33 (Fig. 4B). USP33 bound selectively to the F4
and F5 fragments, which encompass a region upstream of the
C-terminal HECT E3 ligase domain of HERC2. Both the F4 and
F5 fragments have an RCC1-like domain, which consists of a
seven-blade -propeller fold that has been implicated in medi-
ating protein-protein interactions, lipid binding, and nucleo-
tide exchange (44).Within the F4 fragment there is a zinc finger
domain and a DOC (destruction of cyclin B) domain, both
known to mediate protein-protein interactions (45–48). DOC
domains are found exclusively in subclasses of E3 ligases. In the
case of the APC10 subunit of the APC ubiquitin ligase involved
in mitotic progression, the DOC domain has been shown to
enhance binding of the ligase to its substrate, thus promoting
substrate polyubiquitination (45, 47, 49).Of note,USP20 bound
exclusively to the F4 fragment.
To determine whether HERC2 is important for regulating
the degradation of USP33, we generated four HeLa cell lines
each expressing a distinct retroviral shRNA construct against
HERC2. These shRNA constructs silenced HERC2 expression
with varying efficiencies and caused corresponding increases in
USP33 levels (Fig. 4C). Using a cycloheximide chase experi-
ment, we compared the degradation rate of USP33 between
HeLa cells expressing HERC2-ShB versus a nontargeting
shRNA.HERC2 knockdown cells containedmuch higher levels
of endogenous USP33, and no significant reduction of USP33
was detected within a 9-h experiment. In contrast, 75% of
USP33 was degraded in control cells by 9 h (Fig. 4D).
A previous study suggested that the catalytic activity of
HERC2 is not strictly required for all of its functions (38). To
determine whether the E3 ligase activity is required for regulat-
ing USP33, we introduced shRNA-resistant wild-type or cata-
lytically inactive (C4762S) FLAG-tagged HERC2 into the
genome of HERC2-knockdown 293 Flp-In T-Rex cells. The
integration of these constructs was achieved via Flp recombi-
nase-mediated recombination into a single FRT site within the
genome of the parental 293 Flp-In T-Rex cells, and the expres-
sion of the FLAG-tagged HERC2 constructs is doxycycline
inducible. Consistent with our data in HeLa cells, knockdown
of HERC2 caused significant accumulation of USP33. Overex-
pression of wild-type HERC2, but not the C4762Smutant, sup-
pressed this accumulation (Fig. 4E). In fact, cells expressing the
C4762S mutant accumulated an even higher level of USP33,
suggesting a dominant negative effect. These data suggest that
HERC2 functions as a canonical E3 ligase to target USP33 for
proteasomal degradation.
Next, we sought to determinewhetherHERC2 and p97 func-
tion within the same pathway to regulate the degradation of
USP33. Because loss of p97 activity resulted in accumulation of
polyubiquitinated USP33 (Fig. 1I), we asked whether these
ubiquitination modifications are dependent on HERC2. To
address this issue, we modified the inducible p97 knockdown
cell line to express HERC2 shRNA or a nontargeting shRNA.
Upon affinity purification of total ubiquitinated proteins and
immunoblotting for USP33, we found that the accumulation of
ubiquitinated USP33 caused by p97 knockdown was lost in
HERC2-depleted cells (Fig. 5A). Similar results were obtained
FIGURE 5. HERC2 is required for accumulation of ubiquitinated USP33 upon p97 inhibition. A, analysis of ubiquitinated USP33 in p97 knockdown cells
lacking HERC2. HeLa p97-V1 cells were transduced with retrovirus expressing either a control (nontargeting) shRNA or an shRNA against HERC2 (HERC-ShB).
Cells were treated with 1 g/ml doxycycline (dox) for 48 h where indicated, and total cell lysates were isolated. Total ubiquitinated proteins were affinity-
purified using TUBE2-resin, and ubiquitinated USP33 (Ub-USP33) was detected by immunoblotting. B, analysis of ubiquitinated USP33 upon NMS-873 treat-
ment in cells depleted for HERC2. Control (expressing nontargeting shRNA) or stable knockdown cell lines of HERC2 (HERC2-ShB) or USP33 (USP33-ShA) were
treated with 10 M NMS-873 for 12 h. Total cell lysates were isolated, and TUBE2-resin was used to affinity purify total ubiquitinated proteins. Ubiquitinated
USP33 (Ub-USP33) was detected by immunoblotting.
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when p97 activity was inhibited by NMS-873 (Fig. 5B). Strik-
ingly, despite a substantially higher level of total cellular USP33
in HERC2 knockdown cells, the amount of ubiquitinated
USP33 in HERC2 knockdown cells was lower than that in con-
trol cells that were treated with NMS-873. Together, these data
demonstrate that HERC2 and p97 participate in the same path-
way to mediate degradation of USP33 and that HERC2 func-
tions as an E3 ligase upstream of p97.
To understand the role of p97 in the HERC2-dependent
degradation of USP33, we analyzed the interaction between
endogenous HERC2 and USP33 in response to inhibition of
p97. NMS-873 treatment had no effect on the amount of
USP20 that co-immunoprecipitated with HERC2. However,
the amount of co-immunoprecipitated USP33 was substan-
tially increased (Fig. 6A). Likewise, when we performed a
reciprocal co-immunoprecipitation experiment using an
anti-USP33 antibody, the levels of co-immunoprecipitated
HERC2 were also selectively increased (Fig. 6B). These
experiments suggest that p97 may regulate the interaction of
USP33 with HERC2.
DISCUSSION
In this study, we identified a pathway of USP33 degradation
within the ubiquitin-proteasome system.This pathway consists
of three regulators: the E3 ligase HERC2, the AAAATPase p97,
and its heterodimeric cofactor Ufd1-Npl4. Our data support a
model in whichHERC2 polyubiquitinates USP33 to target it for
proteasomal degradation. Subsequently, p97 and its adaptor
Ufd1-Npl4 are required for efficient proteolysis of the polyu-
biquitinated USP33 (Fig. 7).
HERC2 is aHECTdomain-containing E3 ligase that has been
shown to participate in diverse cellular pathways including the
DNA damage response, centrosomemorphogenesis, and ubiq-
uitin-proteasome-dependent protein degradation (38–41).
Because depletion of HERC2 causes dramatic accumulation of
intracellular USP33, decreased USP33 polyubiquitination, and
inhibition of degradation, HERC2 appears to be the predomi-
nant E3 ligase that targets USP33 for proteasomal degradation.
At present, our data do not formally eliminate the possibility
thatUSP33might be regulated by yet another E3 ligase that is in
turn activated by HERC2. However, given that endogenous
HERC2 and USP33 physically interact with each other in co-
immunoprecipitation experiments, it seems likely that USP33
is a bona fide HERC2 substrate.
USP33 has been implicated in a number of disparate cellular
processes. Although the dramatic increase in USP33 levels as a
result of HERC2 or p97 depletion highlights the importance of
these proteins in regulating USP33, we currently do not know
whether HERC2 and p97 act upstream of all processes that
involve USP33.
Further work will be necessary to clarify the mechanism of
p97 in facilitatingUSP33degradation. Because loss of p97 activ-
ity causes increased association between HERC2 and USP33,
themost straightforward interpretation is that p97 functions as
a segregase to dissociateUSP33 fromHERC2 so thatUSP33 can
be efficiently recognized and degraded by the proteasome (Fig.
7). More speculatively, it is also possible that p97 regulates the
activity of HERC2 by controlling its interaction with USP33.
During endoplasmic reticulum-associated degradation, deu-
FIGURE 6. p97 regulates the interaction between HERC2 and USP33. A,
co-immunoprecipitation ofHERC2 andUSP33uponp97 inhibition. HeLa cells
were treatedwith control (DMSO) or 10MNMS-873 for 12 h, and total lysates
were harvested for immunoprecipitation (IP) using an anti-HERC2 antibody.
Co-immunoprecipitated proteins were detected by immunoblotting. B, sim-
ilar to A, except anti-USP33 antibodies were used to immunoprecipitate
USP33.
FIGURE 7.Model of the HERC2-p97-dependent degradation of USP33. HERC2 physically interacts with USP33, leading to USP33 polyubiquitination. p97
and its adaptor complex Ufd1-Npl4 are necessary for the postubiquitination processing of USP33. They facilitate the dissociation of polyubiquitinated USP33
from HERC2, a step that may be important for efficient proteolysis of USP33 by the 26S proteasome.
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biquitinating enzymes have been demonstrated to facilitate
substrate discrimination by E3 ligases (50). Analogously, bind-
ing of USP33 toHERC2may allow the deubiquitinating activity
of USP33 to counteract or balance the E3 ligase activity of
HERC2, thereby controlling substrate polyubiquitination.
The molecules we have identified as USP33 regulators are
involved in pathological conditions in humans andmice.Muta-
tions in p97 are causal for inclusion body myopathy with early
onset Paget’s disease and frontotemporal dementia (IBMPFD)
(51), whereas mutations in HERC2 lead to the rjs (runty jerky
sterile) phenotype in mice (52, 53) and neurodevelopmental
delay with Angelman-like features in humans (54). It will be
interesting to test whether defects in USP33 degradation play a
role in the pathogenesis of these conditions.
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